Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.38 |
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | CA9 | Q16790 | 8/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488952 | 0.98 | CA1 (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL128344 | 0.92 | — | — | |
| SCHEMBL130847 | 0.81 | — | — | |
| SCHEMBL9254838 | 0.81 | USP2 (0.39) | CA1CA2CA9CA12SPHK1 | |
| SCHEMBL6709623 | 0.79 | USP2 (0.42) | CA1CA2CA9SPHK1 | |
| SCHEMBL9316776 | 0.79 | USP2 (0.42) | CA1CA2CA9SPHK1 | |
| SCHEMBL7757009 | 0.79 | USP2 (0.42) | CA1CA2CA9SPHK1 | |
| SCHEMBL28023405 | 0.79 | CA1 (0.38) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16338425 | 0.78 | DNM1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16338300 | 0.78 | DNM1 (0.44) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-103130739-B | There is the compound of thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-102796058-B | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2015-05-13 | — | — | CN | disclosed |
| CN-103130739-A | Compounds having thrombopoietin receptor agonism | SHIONOGI & CO | 2013-06-05 | — | — | CN | disclosed |
| CN-102796058-A | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2012-11-28 | — | — | CN | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070287086-A1 | Colored photosensitive resin composition, color filter, image sensor, and camera system | SONY CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1860502-A1 | Colored photosensitive resin composition, color filter, image sensor, and camera system | Sumitomo Chemical Company, Limited (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| CN-1863783-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-4390548-A | Trans-Δ2 -pge alkylsulphonyl amides | ONO PHARMACEUTICAL CO., LTD. (JP) | 1983-06-28 | — | — | US | disclosed |
| US-4367237-A | THIOPGI-1 DERIVATIVES; OXYTOCICS; PREFERENTIAL | ONO PHARMACEUTICAL CO., LTD. (JP) | 1983-01-04 | — | — | US | disclosed |
| US-4351846-A | 3-Hydroxy and 3-oxo-prostaglandin analogues | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-09-28 | — | — | US | disclosed |
| US-4284581-A | LITHIUM 1,1'-BINAPHTHYL-2,2'-DIOXYALUMINUM HYDRIDE, REDUCING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | CA1 3939/4885CA2 3726/4885CA9 2943/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | CA1 1196/4885CA2 687/4885CA9 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.